TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36044870

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel (LAN) 120 mg every 28 days and temozolomide (TMZ) 250 mg/day for 5 consecutive days every 28-day cycle
Number of subjects: 40
Study: 36045296

Group type: EXPERIMENTAL
Intervention: Non-viral, specifically targeted CAR-T cells
Number of subjects: 0
Study: 36045316

Group type: EXPERIMENTAL
Intervention: Valproic acid 500 mg three times daily
Number of subjects: 30
Study: 36045434

Group type: EXPERIMENTAL
Intervention: Echelon Circular Powered (ECP) stapler
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual Circular Staplers (MCS)
Number of subjects: 100
Study: 36045453

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 36045513

Group type: EXPERIMENTAL
Intervention: Oral brepocitinib
Number of subjects: 0
Study: 36045710

Group type: EXPERIMENTAL
Intervention: EMPOWER information package
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleepwell information package
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 0
Study: 36046132

Group type: EXPERIMENTAL
Intervention: 1% milk, 3 cups/day for 3 months
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group continued habitual intake of total dairy ≤ 1.5 servings/day (<1 cup of milk/day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 73
Study: 36046598

Group type: EXPERIMENTAL
Intervention: PRO-149 OVD
Number of subjects: 36

Group type: COMPARATOR
Intervention: HEC OVD
Number of subjects: 36
Study: 36046613

Group type: EXPERIMENTAL
Intervention: Sick-day protocol administered via interactive voice response system (IVRS)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 315
Study: 36046953

Group type: EXPERIMENTAL
Intervention: Very low-energy diet (VLED) with sleeve gastrectomy (SG)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Very low-energy diet (VLED) with Roux-en-Y gastric bypass (RYGB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Very low-energy diet (VLED) alone (control group)
Number of subjects: 44
Study: 36047431

Group type: EXPERIMENTAL
Intervention: Transitional care combined with conventional care
Number of subjects: 368

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 368
Study: 36047494

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dasatinib with IFN-α
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IFN-α
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dasatinib (in patients with pleural effusions)
Number of subjects: 40
Study: 36047545

Group type: EXPERIMENTAL
Intervention: EVX-01 combined with pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab alone
Number of subjects: 0
Study: 36047604

Group type: EXPERIMENTAL
Intervention: Vascular burden (white matter hyperintensity [WMH] volumes)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mediation analyses
Number of subjects: 120
Study: 36047606

Group type: EXPERIMENTAL
Intervention: Self-reported weight from mobile health app after 6 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Self-reported weight from mobile health app after 12 months
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Discrepancy in self-reported weight after 6 months based on baseline weight
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Discrepancy in self-reported weight after 6 months based on BMI
Number of subjects: 104
Study: 36047900

Group type: EXPERIMENTAL
Intervention: HPV testing on vaginal self-samples using Evalyn Brush
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: HPV testing on vaginal self-samples using Qvintip
Number of subjects: 486

Group type: COMPARATOR
Intervention: HPV testing on matched clinician-taken cervical samples
Number of subjects: 486
Study: 36048266

Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab immune checkpoint inhibitor (ICI) therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Functional lung avoidance planning with chemoradiation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of COPD with perfused lung radiomics size features
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of COPD with perfused lung radiomics shape features
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Perfused lung radiomics size features
Number of subjects: 39
Study: 36048362

Group type: EXPERIMENTAL
Intervention: ATMOS scoring system
Number of subjects: 59

Group type: COMPARATOR
Intervention: Alvarado score
Number of subjects: 59

Group type: COMPARATOR
Intervention: Tzanakis score
Number of subjects: 59
Study: 36048535

Group type: EXPERIMENTAL
Intervention: Olaparib in combination with buparlisib (BKM120)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant olaparib
Number of subjects: 0
Study: 36048848

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 573
Study: 36048877

Group type: EXPERIMENTAL
Intervention: Masitinib (30 μM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled human liver microsomes with NADPH and potassium cyanide
Number of subjects: 0
Study: 36048886

Group type: EXPERIMENTAL
Intervention: Children and adolescents diagnosed with mental disorders (intervention group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sex-matched children from the same postal area (control group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Same parent siblings in the same household close in age +/- 3 years (control group)
Number of subjects: 150
Study: 36048901

Group type: EXPERIMENTAL
Intervention: Post-UART (July 2016-2020)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Pre-UART (2013-June 2016)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 412
Study: 36048970

Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) therapy withdrawal
Number of subjects: 45
Study: 36049283

Group type: EXPERIMENTAL
Intervention: BD Onclarity HPV Assay on first-void urine
Number of subjects: 492

Group type: COMPARATOR
Intervention: Clinician-collected cervical samples
Number of subjects: 492
Study: 36049381

Group type: EXPERIMENTAL
Intervention: EEG monitoring during emergence from anesthesia
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: EEG features during emergence from anesthesia
Number of subjects: 116
Study: 36049537

Group type: EXPERIMENTAL
Intervention: EUS-SWE (left lobe)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EUS-SWE (right lobe)
Number of subjects: 42

Group type: COMPARATOR
Intervention: VCTE
Number of subjects: 42
Study: 36049654

Group type: EXPERIMENTAL
Intervention: Rezivertinib (BPI-7711) at 180 mg orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent.
Number of subjects: 226
Study: 36049817

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study: 36050354

Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 2 kHz (PALS2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 2 kHz (3M2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 10 kHz (PALS10)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 10 kHz (3M10)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 3M electrodes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transcutaneous medium-frequency alternating electrical current stimulation at 2 kHz and 10 kHz
Number of subjects: 25
Study: 36050567

Group type: EXPERIMENTAL
Intervention: Polyaphron dispersion (PAD) technology
Number of subjects: 0
Study: 36050656

Group type: EXPERIMENTAL
Intervention: Dialysis recovery time (DRT) assessment using patient-reported recovery duration post-dialysis.
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Malnutrition-Inflammation Score (MIS) assessment.
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using KDQOL-36 questionnaire.
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Dialysate sodium and number of missed sessions as predictors of DRT.
Number of subjects: 191
Study: 36050661

Group type: EXPERIMENTAL
Intervention: pix2pix GAN synthesized images
Number of subjects: 708

Group type: COMPARATOR
Intervention: Original images
Number of subjects: 708
Study: 36050677

Group type: EXPERIMENTAL
Intervention: Equity-oriented intervention strategies implemented in EDs
Number of subjects: 4771

Group type: EXPERIMENTAL
Intervention: Robust intervention activities at one ED site
Number of subjects: 4771

Group type: COMPARATOR
Intervention: Control group (other ED sites with less robust intervention)
Number of subjects: 4771
Study: 36050684

Group type: EXPERIMENTAL
Intervention: Health motive for meat reduction
Number of subjects: 25393

Group type: EXPERIMENTAL
Intervention: Nutrition motive for meat reduction
Number of subjects: 25393

Group type: EXPERIMENTAL
Intervention: Physical environment motive for meat reduction
Number of subjects: 25393

Group type: EXPERIMENTAL
Intervention: Taste preferences for legume increase
Number of subjects: 25393

Group type: EXPERIMENTAL
Intervention: Social influences, meat avoidance, and meat dislike
Number of subjects: 25393

Group type: EXPERIMENTAL
Intervention: Specific individual characteristics associated with change-inducing motives
Number of subjects: 25393
Study: 36050723

Group type: EXPERIMENTAL
Intervention: TAP device
Number of subjects: 41

Group type: COMPARATOR
Intervention: ADx card
Number of subjects: 41
Study: 36050737

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Higher doses of noradrenaline
Number of subjects: 50
Study: 36050748

Group type: EXPERIMENTAL
Intervention: Patients with AKI
Number of subjects: 19

Group type: COMPARATOR
Intervention: Patients without AKI
Number of subjects: 19
Study: 36050800

Group type: EXPERIMENTAL
Intervention: C allele of rs3135506 in APOA5 (Women)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: C allele of rs429358 in APOE (Men)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: TT genotype of rs2854116 in APOC3
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Risk alleles of APOA5 and APOE or APOC3 and APOE
Number of subjects: 393

Group type: COMPARATOR
Intervention: SNPs in APOB (rs1042034) or LDLR (rs2228671)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Tested SNPs
Number of subjects: 393
Study: 36050804

Group type: EXPERIMENTAL
Intervention: Perioperative oral nutritional support (ONS)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Control group (no ONS)
Number of subjects: 318
Study: 36050896

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB) combined with prolonged exposure therapy (PE)
Number of subjects: 12
Study: 36051040

Group type: EXPERIMENTAL
Intervention: Dose-dense immunochemotherapy with early systemic CNS prophylaxis
Number of subjects: 112
Study: 36051045

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg by mouth once daily in four-week cycles for up to 24 cycles
Number of subjects: 3
Study: 36051466

Group type: EXPERIMENTAL
Intervention: Vigil (gemogenovatucel-T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36051472

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study: 36051549

Group type: EXPERIMENTAL
Intervention: Everyday Life Rehabilitation (ELR) intervention
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Web-based training for staff
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Overall perception of ELR
Number of subjects: 19
Study: 36052222

Group type: EXPERIMENTAL
Intervention: Pre-ACLF patients (n=94)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: ACLF patients at enrollment (n=unknown)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Unstable decompensated cirrhosis patients (n=251)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Stable decompensated cirrhosis patients (n=507)
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Prediction model incorporating precipitants, systemic inflammation, and organ injuries
Number of subjects: 1736
Study: 36052502

Group type: EXPERIMENTAL
Intervention: Enzalutamide, a second-generation AR-targeted therapy
Number of subjects: 0
Study: 36052732

Group type: EXPERIMENTAL
Intervention: Morreton virus (MORV) at a dose of 1 × 10 7 TCID 50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morreton virus (MORV) at a dose of 10 10 TCID 50
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vesicular stomatitis virus (VSV) at a dose of 1 × 10 8 TCID 50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morreton virus (MORV)
Number of subjects: 0
Study: 36052740

Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 3289

Group type: COMPARATOR
Intervention: HFmrEF
Number of subjects: 3289

Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 3289
Study: 36052743

Group type: EXPERIMENTAL
Intervention: Rejuveinix plus dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36053178

Group type: EXPERIMENTAL
Intervention: Decipher genomic classifier
Number of subjects: 226
Study: 36053283

Group type: EXPERIMENTAL
Intervention: Low test dose of pemetrexed (100 μg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Renal function
Number of subjects: 10
Study: 36053289

Group type: EXPERIMENTAL
Intervention: NIRS evaluation with an occlusion test after 8 hours of care
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: NIRS-derived parameters
Number of subjects: 66
Study: 36053381

Group type: EXPERIMENTAL
Intervention: eGFR formulas
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iohexol plasma clearance
Number of subjects: 0
Study: 36053449

Group type: EXPERIMENTAL
Intervention: Extended regimen of ethinylestradiol/drospirenone (EE/DRSP) taken daily for up to 120 consecutive days
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Extended regimen of ethinylestradiol/drospirenone (EE/DRSP)
Number of subjects: 577
Study: 36053558

Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA) for treatment planning of SKMs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Existing web-based institutional website
Number of subjects: 50
Study: 36053572

Group type: EXPERIMENTAL
Intervention: Hypertension management in public and private centers
Number of subjects: 25890

Group type: EXPERIMENTAL
Intervention: Data collection via web interface in Dacima Clinical Suite
Number of subjects: 25890
Study: 36053624

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) in the first postnatal week
Number of subjects: 62145
Study: 36053632

Group type: EXPERIMENTAL
Intervention: Indomethacin (n=1255)
Number of subjects: 16440

Group type: EXPERIMENTAL
Intervention: Ibuprofen (n=3857)
Number of subjects: 16440

Group type: EXPERIMENTAL
Intervention: Surgical closure (n=916)
Number of subjects: 16440

Group type: EXPERIMENTAL
Intervention: Overall PDA treatment (n=5721)
Number of subjects: 16440

Group type: EXPERIMENTAL
Intervention: PDA incidence
Number of subjects: 16440

Group type: EXPERIMENTAL
Intervention: PDA diagnosis
Number of subjects: 16440
Study: 36053658

Group type: EXPERIMENTAL
Intervention: Any intervention during the appointment
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Instructions and/or significant discussions
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Prescriptions
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Laboratory tests and/or medical imaging
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Scheduled follow-up appointments
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Referrals to other professionals
Number of subjects: 1341
Study: 36053786

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin (AD) for 4 or 6 cycles based on interim PET response
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin (AD)
Number of subjects: 34
Study: 36053823

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft
Number of subjects: 0
Study: 36053875

Group type: EXPERIMENTAL
Intervention: Relmacabtagene autoleucel (Carteyva)
Number of subjects: 0
Study: 36053905

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (n=407)
Number of subjects: 1540

Group type: COMPARATOR
Intervention: gemcitabine/nab-paclitaxel (n=655)
Number of subjects: 1540
Study: 36053966

Group type: EXPERIMENTAL
Intervention: Local stroke center group
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Thrombectomy-capable center group
Number of subjects: 1369
Study: 36054234

Group type: EXPERIMENTAL
Intervention: pp65-specific TCR-T cell therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36054490

Group type: EXPERIMENTAL
Intervention: CV301 in combination with nivolumab (C1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CV301 in combination with pembrolizumab (C2)
Number of subjects: 15
Study: 36054522

Group type: EXPERIMENTAL
Intervention: HPP patients with one ALPL variant
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HPP patients with two ALPL variants
Number of subjects: 80
Study: 36054568

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4720

Group type: EXPERIMENTAL
Intervention: Baseline bilirubin
Number of subjects: 4720
Study: 36054609

Group type: EXPERIMENTAL
Intervention: Gaucher disease type 1 (GD1) patients
Number of subjects: 2123
Study: 36055538

Group type: EXPERIMENTAL
Intervention: 1 Hz right hemisphere DLPFC rTMS
Number of subjects: 19
Study: 36055922

Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of triamcinolone acetonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 36055960

Group type: EXPERIMENTAL
Intervention: Body composition at birth (FFMI, FMI, BF%, BMI)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Velocity of BF% from birth to ∼5 y
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Velocity of BMI from birth to ∼5 y
Number of subjects: 1200
Study: 36055962

Group type: EXPERIMENTAL
Intervention: Dietary acrylamide intake (mean ± SD: 30.1 ± 21.9 µg/d)
Number of subjects: 80597
Study: 36056179

Group type: EXPERIMENTAL
Intervention: Bermekimab with Nanoliposomal Irinotecan (Nal-Iri) and 5-Fluorouracil/Folinic Acid (5-FU/FA)
Number of subjects: 22
Study: 36056287

Group type: EXPERIMENTAL
Intervention: Outgrowth endothelial cell-derived conditioned media (OEC-CM)
Number of subjects: 81
Study: 36056317

Group type: EXPERIMENTAL
Intervention: Endoscopic yield
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Histologic yield
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Factors associated with endoscopic yield
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Factors associated with histologic yield
Number of subjects: 2268

Group type: EXPERIMENTAL
Intervention: Indications for EGD
Number of subjects: 2268
Study: 36056321

Group type: EXPERIMENTAL
Intervention: Pharmacological approach in pediatric age (98%)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: MRI-compatible ventilator availability
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Monitoring tools availability
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Anesthesiologist management
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dedicated nurse presence
Number of subjects: 106
Study: 36056348

Group type: EXPERIMENTAL
Intervention: Low education level
Number of subjects: 10000

Group type: COMPARATOR
Intervention: High education level
Number of subjects: 10000
Study: 36056624

Group type: EXPERIMENTAL
Intervention: Patients with MEN2B
Number of subjects: 48
Study: 36056720

Group type: EXPERIMENTAL
Intervention: mHealth access measures
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Internet access
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Computing device ownership
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Fitness tracker ownership
Number of subjects: 2796

Group type: EXPERIMENTAL
Intervention: Computing device ownership for Chinese participants
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Internet access for Chinese participants
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Internet access for participants with other health insurance
Number of subjects: 2796
Study: 36056877

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) torsion measured by cardiovascular magnetic resonance (CMR)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) torsion measured by CMR
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Addition of LV torsion to conventional prognostic factors
Number of subjects: 420
Study: 36057175

Group type: EXPERIMENTAL
Intervention: Astra-Zeneca vaccine and Sputnik V vaccine (complete vaccination)
Number of subjects: 576
Study: 36057440

Group type: EXPERIMENTAL
Intervention: Simulation-based OSCE
Number of subjects: 36
Study: 36057544

Group type: EXPERIMENTAL
Intervention: IgM(N) antibody levels in infected healthcare workers
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: IgG(N) antibody levels in infected healthcare workers
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: IgG(S) antibody levels in infected healthcare workers
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Kinetics of IgM(N) and IgG(N) antibodies
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Kinetics of IgG(S) antibodies
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Kinetics of IgM and IgG antibodies
Number of subjects: 769
Study: 36057890

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone (BV+CHP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, prednisone, and vincristine)
Number of subjects: 0
Study: 36058111

Group type: COMPARATOR
Intervention: Community sanitation coverage of at least one latrine per compound within 50m
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Higher community sanitation coverage
Number of subjects: 360
Study: 36058784

Group type: EXPERIMENTAL
Intervention: HLA-B27-driven altered antibody responses to gut microbiota
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current literature and hypotheses on gut microbiota and HLA-B27-associated disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations for future well-controlled human studies
Number of subjects: 0